Rani Therapeutics oral obesity drug tops subcutaneous exposure in Phase 1a

July 15, 2026 8:00 AM

Rani Therapeutics Holdings (Nasdaq: RANI) reported initial Phase 1a data for RT-114, an oral capsule delivering PG-102, a GLP-1/GLP-2 dual ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found